secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2026-10-30T11:06:12+00:00
Accession:  0001628280-26-068425
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Acumen's Phase 2 ALTITUDE-AD fails primary endpoint; sabirnetug development halted, cash conservation planned
--------------------------------------------------------------------------------

- Phase 2 ALTITUDE-AD missed the primary iADRS endpoint at 18 months vs placebo at both the 35 mg/kg and 50 mg/kg doses; CDR-SB and other key secondary endpoints were not significant.
- Sabirnetug was generally well tolerated; ARIA-E occurred in ~10% of treated participants; PET SUVr showed statistically significant amyloid plaque reduction at weeks 36 and 76.
- Acumen plans to cease development of sabirnetug, including the open-label extension portion of ALTITUDE-AD, and to implement cash conservation measures.
- Company will evaluate strategic options, including its Enhanced Brain Delivery (EBD) program, to maximize shareholder value.
- Additional fluid biomarker and imaging data expected in coming weeks, though Acumen does not expect it to change the trial's efficacy conclusions; CEO Daniel O'Connell commented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000162828026068425/0001628280-26-068425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000162828026068425/abos-20261030.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-068425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer